Author:
Luo Y,Lai X-Y,Tan Y-M,Shi J-M,Zhao Y-M,Han X-Y,Zheng G-F,Zhu X-L,Sun J,Zheng Y-L,Wu G-Q,He J-S,Chen S-Y,Jin A-Y,Xie W-Z,Ye X-J,Cai Z,Lin M-F,Huang H
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference6 articles.
1. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701–4707.
2. Olavarria E, Siddique S, Griffiths MJ, Avery S, Byrne JL, Piper KP et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007; 110: 4614–4617.
3. Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M et al Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 106: 2969–2976.
4. Cwynarski K, Laylor R, Macchiarulo E, Goldman J, Lombardi G, Melo JV et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004; 18: 1332–1339.
5. Chen J, Schmitt A, Giannopoulos K, Chen B, Rojewski M, Döhner H et al. Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner. Int J Oncol 2007; 31: 1133–1139.
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献